Article

Merck's Investigational Hepatitis C Treatment Confirms Proof-of-Concept

A study exploring Merck's experimental hepatitis C virus treatment has provided proof-of-concept for a 6- to 8-week course of triple therapy.

A study exploring Merck’s experimental hepatitis C virus (HCV) treatment has provided proof-of-concept for a 6- to 8-week course of the triple therapy in treatment-naïve patients, including those with cirrhosis.

The C-SWIFT study examined Merck’s HCV treatment regimen comprised of grazoprevir/elbasvir, the company’s NS3/4A protease inhibitor, in combination with sofosbuvir, a nucleotide NS5B inhibitor.

According to Merck, 4 weeks of the triple therapy course resulted in “sub-optimal efficacy,” as only 38.7% of the 102 cirrhotic and non-cirrhotic patients in the study showed sustained virologic response (SVR) after 4 weeks of treatment. However, in double that time, 94.7% of the patients showed an SVR.

The 28 patients who did not achieve SVR at 4 to 8 weeks following treatment relapsed after the end of therapy. Some of these patients had wild type virus, others had elbasvir-resistant viral variants, and 1 patient had variants resistant to both grazoprevir and elbasvir.

The most common complaints related to the regimen were headache (4%), fatigue (2%) and nausea (2%). According to Merck’s press release, the administration of grazoprevir/elbasvir and sofocbuvir was “generally well-tolerated.”

“These interim data provide a compelling proof-of-concept for the potential of an 8- or 6-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Eric Lawitz, MD, vice president of scientific and research development at the Texas Liver Institute and C-SWIFT lead investigator. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com